More patients with hepatitis C will be treated due to a significant price reduction
The maximum coverage of patients with hepatitis C will allow a price reduction of more than 10 times for innovative drugs Sofosbuvir and Daklatasvir. Such a significant decrease became possible thanks to the agreement concluded between LLP SK-Pharmacy and the United Nations Development Program.
According to the acting chairman of the board of LLP “SC-Pharmacy” Berik Sharip, more than 1.5 billion tenge was allocated from the republican budget for the purchase of Sofosbuvir and Daklatasvir preparations.
“Since the United Nations Development Program, which sponsored the procurement of these drugs, managed to achieve a 10-fold reduction in drug prices, these drugs will be purchased for the entire amount allocated. We will try to cover as much as possible patients who are on dispensary records with viral hepatitis C, the most modern treatment for viral hepatitis, “Berik Sharip said.
Note that the drug Sofosbuvir is included by WHO in the list of essential medicines. Treatment of viral hepatitis with drugs Sofosbuvir and Daklatasvir in most cases allows you to finally get rid of the presence of the virus in the body. In addition, such treatment gives significantly fewer side effects than previously used. The purchase of the drug was made possible through an agreement concluded between LLP SK-Pharmacy and the United Nations Development Program.
Press Service of the Ministry of Health of the Republic of Kazakhstan,